cancer panel
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
Exact Sciences Q4 Revenues up 58 Percent; Company to Acquire Ashion Analytics From TGen
Exact's planned acquisition of Ashion, a sequencing lab based in Arizona, builds on the company's licensing of the TARDIS liquid biopsy technology from TGen in January.
Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
Thermo Fisher, Janssen Biotech to Develop CDx for Lung Cancer, Other Indications
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.